ARS Pharmaceuticals(SPRY) - 2024 Q4 - Annual Results

Exhibit 99.1 ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for nef y® (epinephrine nasal spray) Preliminary fourth quarter nef y® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 7:30am PT SAN DIEGO, Jan ...